Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AP-Skin-01
- Development stage
- Preclinical
- Lead developer
- APstem Therapeutics
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Topical
01
Overview
AP-Skin-01 is a novel, "off-the-shelf" allogeneic cell therapy being developed by APstem Therapeutics for the treatment of diabetic ulcers, specifically diabetic foot ulcers (DFUs). The product is derived from adult pluripotent stem cells (APSCs) using the company's proprietary APSC™ and giaSCs™ (genomically-induced Activated Stem Cells) technology platforms. AP-Skin-01 is designed for topical administration to provide full skin structural reconstruction with minimal scar formation. Its therapeutic mechanism involves the promotion of angiogenesis and the reduction of inflammation during the wound repair process. Preclinical data support its potential to accelerate the healing of difficult-to-treat diabetic ulcers. As of 2020, the company had completed an FDA INTERACT meeting to discuss the development path for this investigational product, which is currently in the IND-enabling phase.
- Other names
- allogeneic activated pluripotent stem cellsAPSC
Beyond the preview
Go deeper on AP-Skin-01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AP-Skin-01.